Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 660 clinical trials
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor Copanlisib Given in Combination With the Immunotherapeutic Agents Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Patients with relapsed or refractory follicular or marginal zone lymphoma who have received at least one prior line of therapy will receive Copanlisib IV: day 1, 8, 15 every 28 days Nivolumab IV: Cycle 1 days 1 and 15; then day 1 only Rituximab IV: Cycle 1 days 1, 8, …

cell transplantation
pulmonary disease
pi3k inhibitor
vitiligo
ulcerative
  • 0 views
  • 19 Feb, 2024
PAXG Out in the Country

The objective of this study is to assess the reproducibility of PAXG regimen as first-line/primary chemotherapy in daily clinical practice in Pancreatic Ductal Adenocarcinoma (PDAC) borderline resectable, locally advanced or metastatic patients out of a large volume center.

paclitaxel
pdac
neutrophil count
serum total bilirubin level
ductal adenocarcinoma
  • 0 views
  • 19 Feb, 2024
Safety of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific CAR-T Cells in Adult Patients With Diffuse Large B-cell Lymphoma

This is a single-arm, open-label, dose escalation, phase I study, aiming to evaluate the safety and efficacy of Autologous Humanized Anti-CD19 and Anti-CD20 Dual Specific Chimeric Antigen Receptor (CAR) T-cells in patient with relapsed or refractory diffuse B cell lymphoma.

  • 0 views
  • 19 Feb, 2024
Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

The purpose of this study is to investigate efficacy and safety of Lenalidomide in combination with R-GemOx as first-line treatment of elderly patients with Diffuse large B cell lymphoma.

hiv related lymphoma
gemox
b-cell lymphoma
lymphoma
diffuse large b-cell lymphoma
  • 0 views
  • 19 Feb, 2024
Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.

A prospective multicentre pilot study which includes patients 70 years-old diagnosed of unresectable hilar cholangiocarcinoma (hCCA) 3cm in radial diameter, without evidence of lymph node or distant metastases. Liver transplantation preceded by neoadjuvant radio-chemotherapy will be performed in this selected group. The primary endpoint will be overall survival at 1, …

  • 0 views
  • 19 Feb, 2024
Carotid Doppler and EEOT for Fluid Responsiveness Prediction

Fluid responsiveness prediction prior to fluid challenge administration is a topic of interest, which has been extensively investigated, but remains challenging. In clinical practice, functional hemodynamic tests (FHT) consisting of maneuvers that affect cardiac function and/or heart-lung interaction, have been introduced in order to identify fluid responders and non-responders without …

stroke
  • 0 views
  • 19 Feb, 2024
Topotecan Episcleral Plaque for Treatment of Retinoblastoma

This single site, single-arm, non-randomized, dose escalation phase I toxicity clinical trial will assess primarily the safety and secondarily the efficacy of episcleral topotecan in patients with active residual or recurrent intraocular retinoblastoma in at least one eye following completion of first-line therapy.

platelet count
brachytherapy
renal function
topotecan
intraocular retinoblastoma
  • 0 views
  • 19 Feb, 2024
Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma

The aie of this clinical study is the safety and efficacy of combination therapy for HCC patients.

tuberculosis
antibiotics
total serum bilirubin
combined modality therapy
HIV Infection
  • 0 views
  • 19 Feb, 2024
TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma.

This study will evaluate the safety and effect of transcatheter arterial chemoembolization (TACE)combined with percutaneous transhepatic PD-1 knockout engineered T cell infusion in the Paitents with advanced hepatocellular carcinoma(HCC). Blood and tissue samples will also be collected for research purposes.

  • 0 views
  • 19 Feb, 2024
Zanubrutinib Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia

This study aims to evaluate the efficacy of BTK inhibitor Zanubrutinib combined with Ixazomib and Dexamethasone (ZID) for the newly diagnosed Waldenstrom Macroglobulinemia. This ZID regimen will be given up to 24 months and stopped for observation. We propose this combination will improve the deep remission (VGPR) compared to single …

neutrophil count
dexamethasone
zanubrutinib
indolent lymphoma
chlorambucil
  • 0 views
  • 19 Feb, 2024